StreetAlpha.app
Home › Stocks › TVRD

Tvardi Therapeutics, Inc. (TVRD)

$1.01
▼ −8.18%
LAST CLOSE · NOV 17

Tvardi develops oral small molecule drugs that inhibit STAT3 to treat inflammatory and proliferative diseases. It last closed at $1.01 on Nov 17, down 8.18% on the day.

AI Auto Pilots
Is TVRD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$26.7M
EPS (diluted)
−$2.61
Valuation
Market cap
$13.5M
13.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.3M
At Sep 30
Shareholder equity
$15.5M
Shares outstanding
13.4M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$88.4M−$88.4MFY2021FY2022: −$85.5M−$85.5MFY2022FY2023: −$118.5M−$118.5MFY2023FY2024: −$29.4M−$29.4MFY2024FY2025: −$18.2M−$18.2MFY2025

From TVRD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated TVRD in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 1286.1% upside

Based on 1 analyst who set a price target on TVRD in the past 90 days. The average target is $14.00, with a high of $14.00 and a low of $14.00, compared with the last close of $1.01.

Low $14.00Avg $14.00High $14.00
Blue marker: last close $1.01
Highest target$14.00
Average target$14.00
Lowest target$14.00
Latest rating changes
LUCID CAPITAL MARKETSAssumed coverage
Sep 8Buy$14
BTIGTarget lowered
Jul 30Buy$15 → $5
Raymond JamesUpgrade
Jul 8Buy$10
BTIGReiterated
Jul 7Buy$15
HC Wainwright & Co.Initiated
Jun 8Buy$9
DateFirmActionRatingPrice target
Sep 8LUCID CAPITAL MARKETSAssumed coverageBuy$14
Jul 30BTIGTarget loweredBuy$15 → $5
Jul 8Raymond JamesUpgradeBuy$10
Jul 7BTIGReiteratedBuy$15
Jun 8HC Wainwright & Co.InitiatedBuy$9
Loading…

Technical Analysis

TVRD · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 154% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot S1 at $0.98, and the nearest resistance the Pivot at $1.03.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 14.9%/day
Key levels
$5.6952 week high+463.4%
$2.56200 day average+153.5%
$1.74100 day average+72.3%
$1.2050 day average+18.8%
$1.09Swing high (Oct 21)+7.9%
$1.06Pivot R1+5.0%
$1.03Pivot+2.0%
$1.0120 day average+0.0%
$1.01Last close
$0.98Pivot S1−3.0%
$0.97Swing low (Oct 12)−4.0%
$0.7752 week low−23.8%
Indicators
RSI (14)45.53Middle of its rangeNeutral
MACD0.00Above its signal lineBullish
Stochastic38.7Middle of its rangeNeutral
ADX (14)37.7Trending up
Williams %R-71.7Oversold below −80, overbought above −20Neutral
CCI (20)6.8Oversold below −100, overbought above 100Neutral
Rate of change+21.0%Change over 10 sessionsBullish
ATR (14)$0.15Typical daily range, 14.9% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for TVRD

What happened before

See how TVRD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in TVRD in the last 90 days.

Loading…

See today’s whale options flow across the market →

TVRD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲36 buying vs 29 selling
  • ▲Held by funds +10.4 pts
  • ▲Funds holding +2
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6260+3.3%
In funds' top 1000–
Held by funds27.1%16.7%+10.4 pts
New / increased21 / 1513 / 7+80.0%
Reduced / sold out11 / 1823 / 20−32.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TVRD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVRD is in one of them and how their past TVRD trades turned out.

TVRD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TVRD in an article yet. Here's the latest on the wider market.

About Tvardi Therapeutics

Tvardi is a biopharmaceutical company based in Sugar Land, Texas. It is developing oral, small molecule drugs that aim to block STAT3, a protein inside cells that drives inflammatory and cell growth diseases. Its TTI-101 candidate is being tested in patients with liver cancer and has also been studied in idiopathic pulmonary fibrosis, a lung disease. The company does not yet sell products, and its drugs are still in clinical trials.

Headquarters
Sugar Land, TX